A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the safety and effectiveness of the SafeFlo filter for permanent protection against pulmonary emboli. All patients will be selected to receive the filter according to the stated inclusion / exclusion criteria after consultation between the attending physician and interventional radiologist. Patients with a permanent implantation will be followed for up to 6 months. Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of permanent filter patients considered to be a clinical success will be the primary efficacy parameter.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Traditional indications for vena cava filter in patients with established DVT or PE, including (40):
Patients with proven Pulmonary Embolus (PE) or Deep Vein Thrombosis (DVT) and one or more of the following:
Contraindication to anticoagulation
Complication of anticoagulation
Failure of anticoagulation
Recurrent PE despite adequate anticoagulation therapy
Inability to achieve adequate anticoagulation
Poor compliance with anticoagulation medications
Extended indications for vena cava filter placement in patients with established DVT or PE, including the following (31, 40):
Large free-floating thrombus in the iliac vein or IVC;
Following massive PE in which recurrent emboli may prove fatal;
During/after surgical or transcatheter embolectomy;
Filter placement in high-risk trauma and orthopedic patients:
High risk trauma or orthopedic patients who cannot receive anticoagulation because of increased bleeding risk, and have one or more of the following injury patterns (31, 40):
Severe closed head injury (GCS < 8);
Incomplete spinal cord injury with para or quadriplegia;
Complex pelvic fractures with associated long-bone fractures;
Multiple long bone fractures.
Patients undergoing long-term immobilization (e.g., ICU or Surgical oncology)
All patients under 18 years of age.
All patients undergoing emergency procedures.
All patients with abnormal IVC anatomy or pathology of the IVC such as thrombosis or tumor which prevent safe filter implantation.
All patients with an IVC diameter which precludes oversizing of the filter platform.
All patients with active infection / bacteremia.
All patients with sensitivity to contrast media.
Uncorrectable severe coagulopathy (e.g., patients with liver or multisystem failure).